Ranbaxy signs new R&D agreement with GSK

Published on Tue, Feb 06, 2007 at 19:24 |  Source : Moneycontrol.com

Updated at Tue, Feb 06, 2007 at 20:30  

39737 Investors following Ranbaxy Labs. Share this News with them.
0
0
Share on Tumblr

RELATED NEWS

ALSO READ

Ranbaxy Laboratories Limited (Ranbaxy) announced today that the Company and GlaxoSmithKline (GSK) have signed a new multiyear R&D agreement that modifies and expands the terms of their strategic alliance established in 2003 to provide Ranbaxy expanded drug-development responsibilities and further financial opportunities.

 

Under the original agreement, Ranbaxy conducted the optimization chemistry required to progress drug leads to the stage of candidate selection. Under the new agreement, Ranbaxy will advance leads beyond candidate selection to completion of clinical proof of concept. GSK thereafter will conduct further clinical development for each program and take resulting products through the regulatory approval process to final commercialization.

 

Ranbaxy could receive over $100 Mn in potential milestone payments for a product developed by Ranbaxy and subsequently launched by GSK in multiple indications and up to double digit royalties on worldwide net sales. Ranbaxy will retain the right to co-commercialize the products in India. The new milestones and royalties will apply both to future drug discovery programs and to the two programs currently ongoing  at Ranbaxy,  that were commenced under the original agreement with GSK.

 

This expanded alliance envisages potential work in a wide range of therapeutics of interest to GSK, including anti-infectives and metabolic, respiratory and oncology products. While recognizing the performance and clinical-development capabilities of Ranbaxy, it also conforms to the remit of GSK's Center of Excellence for External Drug Discovery ("CEEDD").

 

contd on page 2...

  

Trending News

Business News

Sony to roll-out ICS update next week, Xperia PLAY gets the boot
Reebok execs named in Rs 870 cr fraud denied anticipatory bail "Reebok execs named in Rs 870 cr fraud denied anticipatory bail"

Live Updates: KKR favourites in last-over battle

Rel Comm Q4 Cons Net Revenue Up 5% At `5,310 Cr (QoQ)

The latest earning numbers FIRST on CNBC-TV18
Videos

May 25 2012, 22:26

NHPC posts profit amid capacity addition, delay woes

- in Results Boardroom

Interviews

May 27 2012, 11:52 | Source: CNBC-TV18

Expect to maintain EBIDTA margin ahead: Wockhardt  

May 27 2012, 11:00 | Source: CNBC-TV18

e-commerce market in India: What's in store?  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!